STOCK TITAN

Inhibikase Therapeutics, Inc. (IKT) Net Income by Year

IKT

Inhibikase Therapeutics, Inc. reported a net loss of $48.3M in fiscal year 2025. This represents a decrease of 75.4% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Inhibikase Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income -$48.3M
YoY -75.4%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IKT Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY25DEF 14AFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Net Income-$48.3M-75.4%-$27.5M-44.6%-$19.0M-5.4%-$18.1M-22.1%-$14.8M-419.2%-$2.8M

IKT Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$19.6M-97.6%-$16.4M-19.8%N/A-$11.9M-106.5%-$9.9M-99.9%-$13.7M-194.2%N/A-$5.8M-25.7%-$5.0M+14.2%-$4.6M-3.8%-$4.2M+2.4%-$4.6M-2.2%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Inhibikase Therapeutics, Inc. financials

Frequently Asked Questions

What was Inhibikase Therapeutics, Inc.'s net income in fiscal year 2025?

Inhibikase Therapeutics, Inc. reported a net loss of $48.3M in fiscal year 2025.

How fast is Inhibikase Therapeutics, Inc.'s net income growing?

Inhibikase Therapeutics, Inc. (IKT) net income fell by 75.4% year over year, from -$27.5M to -$48.3M in fiscal year 2025.

How has Inhibikase Therapeutics, Inc.'s net income changed over the years?

Across the 6 fiscal years this page covers, Inhibikase Therapeutics, Inc. (IKT) net income went from -$2.8M in fiscal year 2020 to -$48.3M in fiscal year 2025.

Inhibikase Therapeutics, Inc. (IKT) reported -$19.6M in net income in Q2 2026. This represents a decrease of 97.6% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Inhibikase Therapeutics, Inc. (IKT) reported on that line in every period on record.